{"url_path":"/sec/lrmr/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-224087-index.html","accession_number":"0001193125-26-224087","cik":"0001374690","ticker":"LRMR","issuer_name":"Larimar Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-224087-index.html","primary_entity_key":"0001374690","primary_entity_name":"Larimar Therapeutics, Inc."},"word_count":76,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings\n\nFrom time to time, we are subject to claims in legal proceedings arising in the normal course of business. To our knowledge, during the three months ended March 31, 2026, there were none, and as of the date of this Quarterly Report, there are no threatened or pending legal actions that could reasonably be expected to have a material adverse effect on our business, financial condition, results of operations, or cash flows."}